(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Trial details
- Registry ID
- NCT05907954
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as IDE 196; IDE196; LXS196
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaNCT05907954 | IDEAYA Biosciences | Phase 2 | Active not recruiting | 2027-04-30Estimated |
| Neoadjuvant Darovasertib in Primary Uveal MelanomaNCT07015190 | IDEAYA Biosciences | Phase 3 | Recruiting | 2030-10Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |